Karl Beutner, MD, PhD
Co-Founder, Chief Executive Officer, Chief Medical Officer
Karl Beutner, MD, PhD, is DermBiont’s CEO and CMO leading drug development efforts.
Dr. Beutner will apply his extensive background in dermatology and infectious disease drug development to build DermBiont's clinical development capabilities.
Karl brings more than 25 years of experience in medicine most recently from Anacor Pharmaceuticals where he served as Chief Medical Officer in addition to serving as a senior executive with several established healthcare organizations and as a practicing physician.
Robert M. Brucker, PhD
Co-Founder, Chief Scientific Officer
Dr. Robert Brucker leads research efforts at DermBiont and received his B.S. in Biology from the University of Mount Union in 2007 and earned a PhD in Biomedical Sciences from Vanderbilt University in 2013.
He is currently a Rowland Junior Fellow at Harvard University where he runs a research program on applied microbiomes.
Robert has 19 publications related to host-microbe associations (published in journals Nature ISME, Science, and Nature Communications), including experimental probiotic trials for antifungal activity.
He has over a decade of genetics, microbiology, and applied microbiota experience.
Co-Founder, Chief Business Officer
Nick's investment expertise spans across asset classes with an extensive focus on microbiome oriented companies across all stages of venture capital.
Nick is a Managing Partner at Olive Tree Capital; he led his last company through acquisition and has successfully seeded and structured companies across multiple industries.
His passion for the Microbiome originates from personal experiences with skin infections and c-diff.
Nick graduated with honors from Boston University’s Questrom School of Business and started his career in commodity markets at CPM Group in New York.
Gerardo Toledo, PhD
Scientific Advisor, Microbial Discovery
Gerardo leads microbial discovery at DermBiont.
Prior to joining the company, he served as VP of Discovery at Indigo Agriculture, Inc. alongside David Perry and Geoff von Maltzahn, building lab infrastructure, IP, and experimental validations.
Enabled Indigo’s growth from seed stage to commercial launch of agriculture products based on the plant microbiome and a $100M Series C round of funding.
Before Indigo, Gerardo spent eight years as Sr. Director with J. Craig Venter at Synthetic Genomics Inc. (SGI), where he established the microbial discovery platform.
He came to SGI from 6 years as a scientist at Diversa Corp. (now Verenium-BASF). Gerardo holds a PhD from Scripps Institution of Oceanography (UCSD) in La Jolla, CA.
Reid N. Harris, PhD
Scientific Advisor, Microbiome
Professor Reid Harris received his B.S. with honors in Zoology at Duke University, a Masters of Science in Zoology from the University of Maryland and a PhD in Zoology and Mathematics from Duke University.
He is a Full Professor at James Madison University, a Research Associate at the Smithsonian Conservation Biology Institute, and Director of the International Disease Mitigation for the Amphibian Survival Alliance.
Reid’s research focus involves microbial ecology of amphibian skin, especially in the context of bacterial interactions with lethal skin fungus.
He was elected fellow of the American Association for the Advancement of Science and has 40 publications on fungal skin diseases and probiotic mitigation.
Kevin P.C. Minbiole, PhD
Scientific Advisor, Chemistry
Professor Kevin Minbiole received his B.S. in Biochemistry at the University of Notre Dame (summa cum laude) in 1996 and his PhD in organic chemistry from the University of Pennsylvania in 2001.
He was an American Cancer Society-funded postdoctoral fellow at Harvard University for 2 years before joining the Department of Chemistry at James Madison University.
He moved to Villanova University in 2011, where he is currently an Associate Professor of Chemistry.
Professor Minbiole has spent several semesters as a Visiting Professor at MIT and the University of Pennsylvania.